NCT03159117已完成1 期
A Phase I Open-Label Dose Escalation of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- the Recommended Phase 2 Dose
研究概览
简要总结
The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06688992. Before this study, PF-06688992 has never been given to people.
PF-06688992 is a targeted therapy for people with cancer. The investigators linked a chemotherapy drug to an antibody (protein found in the blood). The antibody will connect to GD3 which is found on most melanomas but on very few other cells in the body. The investigators hope that in this way, it will deliver this chemotherapy directly to the melanoma and not to normal tissues.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of melanoma confirmed at MSKCC
- •Measurable unresectable Stage III or IV Malignant Melanoma and Response Criteria in Solid Tumors [RECIST], Version 1.
- •Patients must have progressed on prior approved checkpoint inhibitor therapy, not tolerated approved checkpoint inhibitor therapy, or have a contraindication to approved checkpoint inhibitors. Patients with stable disease after approved checkpoint inhibitor therapy will also be eligible.
- •Patients whose melanomas harbor a BRAF V600E or V600K mutation must have progressed on a RAF inhibitor. Patients who had to discontinue RAF inhibitor therapy because of toxicity but who did not progress will be eligible unless they responded to therapy. In that case, they will not be eligible unless they progress.
- •Age ≥ 18 years
- •ECOG performance status 0-
- •Adequate Bone Marrow Function as defined by:
- •°≥1,500/mm^3 or ≥ 1.5 x 10^9/L;
- •Platelets ≥ 100,000/mm3 or ≥ 100 x 109/L;
- •Hemoglobin ≥ 9 g/dL.
- •Adequate Renal Function as defined by:
- •Serum creatinine ≤ 1.5 x upper limit of normal (ULN); or
- •Estimated creatinine clearance ≥ 60 mL/min as calculated using the method standard for the institution.
- •Adequate Liver Function as defined by:
- •Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome;
- •Aspartate and Alanine Aminotransferase (AST & ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if there is liver involvement secondary to tumor;
- •Alkaline phosphatase ≤ 2.5 x ULN; (≤ 5 x ULN in case of bone metastasis).
- •QTc interval < 470 msec.
- •Recovery from all prior surgical or adjuvant treatment-related toxicities, to Baseline status, or a CTCAE Grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia. Post-surgical pain will not be considered a basis for exclusion.
- •Negative serum/urine pregnancy test (for women of childbearing potential).
- •Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
- •Evidence of a signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
- •Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.
排除标准
- •Patients with known symptomatic brain metastases requiring steroids.
- •Patients with previously diagnosed brain metastases are eligible as long as they do not require CNS-directed therapy (including corticosteroids). If the patient has had radiation therapy or surgery, then they should have completed treatment and have discontinued corticosteroids for at least 2 weeks and must be neurologically stable.
- •Patients with uveal melanoma will not be eligible as these tumors show low expression of GD
- •Major surgery, radiation therapy or systemic anti-cancer therapy within 2 weeks of starting study treatment.
- •Presence of ≥ Grade 2 peripheral neuropathy.
- •Significant prior infusion reaction to monoclonal antibodies that required treatment with systemic steroids.
- •Active and clinically significant bacterial, fungal or viral infection.
- •Known infections with hepatitis B (HBV) or hepatitis C (HCV),
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness not controlled (with undetectable viral load) on HAART therapy. Patients on HAART with undetectable viral loads may be eligible per PI judgment.
- •Pregnant or breastfeeding; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after last dose of investigational product.
- •Patients currently receiving active treatment for melanoma.
- •Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack.
- •Any ongoing cardiac dysrhythmias of NCI CTCAE Grade >2, NCI CTCAE Grade 4 atrial fibrillation, or QTcF interval >470 msec, except for documented Right Bundle Branch Block, at screening.
- •Chronic Bronchitis or Emphysema requiring oxygen therapy within the last 6 months.
- •Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality or uncontrolled hypertension that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究组 & 干预措施
PF 06688992
Experimental
This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
干预措施: PF-06688992 (Drug)
结局指标
主要结局
the Recommended Phase 2 Dose
时间窗: 1 year
using a Bayesian dose escalation scheme
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Autologous Polyclonal Tregs for LupusLupus Erythematosus, CutaneousLupus Erythematosus, DiscoidLupus Erythematosus, SystemicNCT02428309National Institute of Allergy and Infectious Diseases (NIAID)1
终止
1 期
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsBreast CancerPulmonary CancerNon-Small-Cell Lung CarcinomaProstatic CancerProstate CancerLung CancerGastric CancerStomach CancerNCT00511576Mirati Therapeutics Inc.54
招募中
1 期
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentAdvanced or Metastatic Solid TumorLiver FailureNCT04617522Gilead Sciences30
已完成
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsAdvanced Solid TumorsMetastatic Solid TumorsNCT05487235Genentech, Inc.57
已完成
1 期
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) PatientsLeber Hereditary Optic NeuropathyNCT02064569GenSight Biologics19